semaglutide cardiovascular outcomes news 2025 october benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials | BMC Cardiovascular Disorders Cardiovascular Risks after GLP-1 Discontinuation

However, the medication discontinuation rates were greater than 50% across all doses compared to 40% with placebo, with the most common adverse events (AE) being gastrointestinal in nature [27]

Updated Schedule: ADA Boot Camp, Tech, MNT & More Live in Beautiful San Diego Oct 22-23, 2026 Re-Ignite your Passion & Prepare for Diabetes Certification Exams Earn 30+ CEs: AMA PRA Category 1 Credits , ACPE, ANCC, and CDR

04 Monitoring and Adjustments Regular check-ins with your healthcare provider ensure your treatment remains both safe and effective

Do not delay in contacting a professional on account of something you have read in this article or on this website. The information provided in this blog is for educational purposes only and should not be considered medical advice or legal advice